Leena Gandhi | Vice President Of Immuno Oncology Development
Eli Lilly and Company

Leena Gandhi, Vice President Of Immuno Oncology Development, Eli Lilly and Company

Dr. Leena Gandhi currently serves as Vice President, Immuno-Oncology Development at Eli Lilly.  She previously was an associate professor of medicine at NYU Perlmutter Cancer Center where she served as Director of Thoracic Medical Oncology from 2016-2018 and prior to that she worked as a thoracic oncologist in the Early Drug Development Center at Dana-Farber Cancer Institute.  Her focus of research has been on novel therapeutics in lung cancer with a focus on immuno-oncology and biomarkers of immunotherapy response in lung cancer as well as modulation of the immune microenvironment by chemotherapies and other therapies.  She was a lead investigator in defining PD-L1 biomarkers used for pembrolizumab therapy in NSCLC.


Day 2, April 8 @ 09:40

Panel: Targeted approaches to combinations, what’s working?

  • What strategies can we use to identify the best combinations?
    • Using immunology as a guide?
    • Combinations of any active compound?
  • What are the major mechanisms we need to focus on?
  • How successful have targeted combinations been so far?
    • IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents
  • What are the best biomarkers for combination studies?
  • What major challenges remain?
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates